Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

    Abstract

    Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

    OriginalsprogEngelsk
    TidsskriftAACE clinical case reports
    Vol/bind5
    Udgave nummer12
    Sider (fra-til)2085-2087
    Antal sider3
    ISSN2376-0605
    DOI
    StatusUdgivet - dec. 2017

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine'. Sammen danner de et unikt fingeraftryk.

    Citationsformater